Boehringer Ingelheim Pharmaceuticals and Eli Lilly have announced that the US Food and Drug Administration (FDA) has approved Tradjenta (linagliptin), a dipeptidyl peptidase-4 inhibitor used to lower blood sugar in adults with type 2 diabetes.
Tradjenta can be used as monotherapy or in combination with metformin, sulfonylurea or pioglitazone.
Go deeper with GlobalData
When used as monotherapy, Tradjenta showed significant A1C reductions of up to 0.7%, and reductions of 0.5% when used in combination with pioglitazone.
Adverse affects observed with the use of the drug include nasopharyngitis, hypoglycaemia, and pancreatitis.
Tradjenta is under regulatory review in the EU and Japan.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
